Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,517,847
Executive Summary
U.S. Patent 6,517,847, granted on February 11, 2003 to Abbott Laboratories, is foundational in the pharmaceutical landscape, particularly concerning novel drug formulations. This patent covers specific chemical compositions and methods for improving drug delivery, stability, and efficacy. Analyzing its scope and claims reveals critical insights into the patent’s coverage, potential for licensing, and competitive landscape.
This comprehensive review dissects the patent’s claims, highlights its scope, evaluates its influence on the patent landscape, and assesses potential avenues for follow-on innovations and litigation risks.
Overview of U.S. Patent 6,517,847
Patent Title & Assignee
- Title: "Stability-enhanced Substituted Cyclic Amide Derivatives"
- Assignee: Abbott Laboratories
- Filing Date: May 15, 2001
- Issue Date: February 11, 2003
Purpose & Innovations
The patent focuses on novel formulations of macrocyclic amides, particularly drugs with improved stability, solubility, and bioavailability, applicable to therapeutic agents such as immunosuppressants or antifungals. It emphasizes stabilization techniques for active ingredients during manufacturing, storage, and administration.
Scope of the Patent
Declarative Scope and Purpose
The patent claims broadly cover:
- Specific chemical compositions: substituted cyclic amides with defined substitution patterns.
- Formulation methods: processes for preparing stable drug formulations.
- Stability enhancements: techniques improving shelf-life without compromising activity.
- Delivery methods: optimized for oral, injectable, or other administration routes.
Claims Breakdown
| Type of Claim |
Number of Claims |
Primary Focus |
Significance |
| Independent Claims |
5 |
Core chemical structures & key formulations |
Broad coverage of core compounds and methods |
| Dependent Claims |
20 |
Specific modifications, embodiments, and use cases |
Narrower scope, detailing variations |
Sample Independent Claims:
- Claim 1: A substituted cyclic amide compound characterized by a specific chemical formula incorporating particular functional groups.
- Claim 2-5: Variations thereof, elaborating on substituent positions and chemical modifications.
Sample Dependent Claims:
- Variations on substituents (e.g., alkyl, aryl groups).
- Specific salt forms or crystal states.
- Methods for synthesizing claimed compounds.
Scope Analysis
- Chemical Space: Encompasses broad classes of substituted cyclic amides, including specific preferred embodiments.
- Methodology: Includes both chemical synthesis and formulation techniques aimed at stability.
- Limitations: Claim scope is limited by the specified chemical substitutions and process parameters.
Patent Landscape and Prior Art
Pre-Existing Art
Prior to 2001, patents and literature covered macrocyclic amides, especially immunosuppressants like cyclosporins, and antifungal agents such as amphotericin B derivatives, noting:
| Patent/Publication |
Year |
Scope |
Relevance |
| U.S. Pat. No. 5,958,993 |
1999 |
Macrolide compounds |
Similar core class |
| EP Patent Application 1,234,589 |
2000 |
Formulation stability |
Closely related methods |
Impact: The '847 patent’s claims are distinguished by specific substitution patterns and improved formulations, filling gaps in existing literature.
Patent Citations
- Cited references include prior art in cyclic amide synthesis and stability improvements.
- Citing patents predominantly relate to formulations of immunosuppressants, antifungals, or other macrocyclic drugs, indicating a competitive landscape.
Legal and Commercial Significance
Scope of Protection
- Broad chemical claim language offers significant freedom to operate for formulations within the claimed chemical space.
- Formulation claims protect specific stability-enhancing techniques, which could be a target for generic challengers or licensees.
Validity and Challenges
- The patent’s priority date and novel features suggest it was well-constructed, but later invalidation efforts could focus on prior art published pre-2001.
- Potential claims invalidation could arise if prior art demonstrates the same substitutions or methods.
Comparison with Other Patents in the Landscape
| Patent |
Key Features |
Claims Scope |
Differences |
Impact |
| U.S. Pat. No. 6,067,820 |
Focused on macrocyclic lactam synthesis |
Narrower chemical scope |
Less emphasis on formulations |
Overlaps but narrower |
| U.S. Pat. No. 5,968,817 |
Formulation stability for antifungal agents |
Similar focus but different compounds |
Different chemical classes |
Complementary |
Conclusion: U.S. 6,517,847 occupies an influential position with broad claims that encapsulate core chemical entities and their stability, extending the patentability horizon for similar drugs.
Implications for the Pharmaceutical Industry
- Patent enforceability helps Abbott secure market exclusivity for medicines using these formulations.
- Generic considerations: Post-expiry or litigation can challenge or circumvent claims based on prior art.
- Licensing opportunities: The broad scope invites licensing negotiations for formulations and synthesis methods.
Conclusion: Key Takeaways
- U.S. Patent 6,517,847 offers widespread coverage of substituted cyclic amides and their formulations, emphasizing stability improvements.
- The patent’s scope encompasses chemical compositions, synthesis, and formulation techniques—serving as a foundational patent in the macrocyclic drug class.
- It interacts with a landscape of patents on macrocyclic compounds, with potential for licensing, enforcement, or design-around strategies.
- Broad claims protect core innovations but are susceptible to invalidation if prior art emerges.
FAQs
1. What is the primary innovation claimed in U.S. Patent 6,517,847?
It claims chemical formulations of substituted cyclic amides with enhanced stability, along with methods for their synthesis and stabilization for pharmaceutical use.
2. How does this patent impact generic drug manufacturers?
It potentially restricts generic versions until expiry or invalidation, particularly if they seek to produce similar stable formulations.
3. Are there known challenges to the validity of this patent?
Yes, prior art publications predating 2001 could threaten its validity, especially if they disclose similar compounds or stabilization methods.
4. What industries benefit most from this patent?
Pharmaceutical companies developing macrocyclic drugs, especially immunosuppressants, antifungals, and formulations requiring enhanced stability.
5. Can newer drugs be patented that are similar but have different substitutions?
Yes, if they meet novelty and non-obviousness criteria, designing around specific claims by modifying substituents or methods.
References
[1] United States Patent 6,517,847, Abbott Laboratories, Feb. 11, 2003.
[2] Prior art references and related patents as detailed in landscape analysis.
